The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
Shipping of the assay, Cepheid's eighth product release in 2014, is anticipated to begin in February 2015.
With the precision of PCR, the method could ultimately be used to build faster, simpler diagnostics.
The new claims allow for pre-transplantation testing of organ and tissue donations for HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.
The platform — called NINA for non-instrumented nucleic acid amplification — is designed to work with a wide range of isothermal amplification methods.
Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.
The firm said the product is the first HIV viral load assay with a dual claim for diagnosis and treatment monitoring.
MOgene, a genomics services provider, launched a new subsidiary this week called MOgene Clinical Diagnostics (MOgeneDx) to provide next-generation sequencing-based testing for infectious diseases and immune disorders.
Two new studies demonstrate improved methods using droplet digital PCR to detect very low viral loads in HIV-positive patients, pushing the detection threshold lower than that of real-time PCR.
Isothermal molecular method incubated in the armpit allows researchers to detect HIV-1 DNA in proof-of-concept study.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.